🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA register with Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair as lead sponsor. Synced 26 Sep 2026
7Current trials
0Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair is the lead sponsor of 7 current clinical trials in our USA register. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Phase EARLY_PHASE1. The drugs named most often in its trials are BCG Vaccine Mix for percutaneous use and 9vHPV Vaccine. The most-studied condition is HPV Infection.

ClinicalTrials.gov trials by status

  • Active, closed7100%

Trials by phase

  • Phase EARLY_PHASE1343%
  • Phase 2/3343%
  • Phase 1114%
01

Clinical trials sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
NCT06959563 · ClinicalTrials.gov ↗ · HPV Infection
Phase EARLY_PHASE1 Active, closed 2025-04 USA
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
NCT02403505 · ClinicalTrials.gov ↗ · Rectal Cancer
Phase 1 Active, closed 2021-12 USA
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
NCT03348670 · ClinicalTrials.gov ↗ · Prostate Cancer
Phase 2/3 Active, closed 2023-08 USA
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
NCT07145333 · ClinicalTrials.gov ↗ · SCLC
Phase 2/3 Active, closed 2025-08 USA
Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
NCT03305341 · ClinicalTrials.gov ↗ · Covid19
Phase EARLY_PHASE1 Active, closed 2025-05 USA
Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix
NCT07182838 · ClinicalTrials.gov ↗ · HIV Infections
Phase EARLY_PHASE1 Active, closed 2025-09 USA
Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms
NCT06062810 · ClinicalTrials.gov ↗ · Breast Cancer
Phase 2/3 Active, closed 2025-06 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair trials

7 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA70

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in HPV Infection

SponsorTrials
Frantz Viral Therapeutics3
Fujian Maternity and Child Health Hospital3

Sponsors with the most current trials registered for this condition.

06

Questions about Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair trials

How many clinical trials does Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair sponsor?

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair is the lead sponsor of 7 current trials on ClinicalTrials.gov in our USA register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair trials recruiting?

Not at the moment. None of its 7 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Which drugs is Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are BCG Vaccine Mix for percutaneous use (4) and 9vHPV Vaccine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.